Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.

Cancer research - 15 Mar 2011

Cao Zhongwei, Fan-Minogue Hua, Bellovin David I, Yevtodiyenko Aleksey, Arzeno Julia, Yang Qiwei, Gambhir Sanjiv Sam, Felsher Dean W

Abstract excerpt

MYC is a potential target for many cancers but is not amenable to existing pharmacologic approaches. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) by statins has shown potential efficacy against a number of cancers. Here, we show that inhibition of HMG-CoA reductase by atorvastatin (AT) blocks both MYC phosphorylation and activation, suppressing tumor initiation and growth in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Hep G2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Proto-Oncogene Proteins c-myc

Share to Pyrroles

Share to rac GTP-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21262914
DOI: 10.1158/0008-5472.CAN-10-3367
PMCID: PMC3059327

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.PMID 21262914Read ↗

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.Semantic proximity Read ↗

Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas.Semantic proximity Read ↗

Mevalonate Pathway and Human Cancers.Semantic proximity Read ↗

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cellsSemantic proximity Read ↗

ICMT supports BRAFV600E-driven tumor growth by membrane targeting of the CAAX protein INPP5E.Semantic proximity Read ↗

The C-terminus of the oncoprotein TGAT is necessary for plasma membrane association and efficient RhoA-mediated signaling.Semantic proximity Read ↗

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.Semantic proximity Read ↗

Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.Semantic proximity Read ↗

Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism.Semantic proximity Read ↗

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.Semantic proximity Read ↗

Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation.Semantic proximity Read ↗

Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.